MXPA03010875A - AMIDAS DE ACIDOS ANTRANILICOS CON CADENA LATERAL DE HETEROARILSULFONILO, PROCEDIMIENTO PARA SU PREPARACIoN SU EMPLEO COMO MEDICAMENTO O AGENTE DE DIAGNOSTICO ASI COMO PREPARADOS FARMACeUTICOS QUE LAS CONTIENEN. - Google Patents

AMIDAS DE ACIDOS ANTRANILICOS CON CADENA LATERAL DE HETEROARILSULFONILO, PROCEDIMIENTO PARA SU PREPARACIoN SU EMPLEO COMO MEDICAMENTO O AGENTE DE DIAGNOSTICO ASI COMO PREPARADOS FARMACeUTICOS QUE LAS CONTIENEN.

Info

Publication number
MXPA03010875A
MXPA03010875A MXPA03010875A MXPA03010875A MXPA03010875A MX PA03010875 A MXPA03010875 A MX PA03010875A MX PA03010875 A MXPA03010875 A MX PA03010875A MX PA03010875 A MXPA03010875 A MX PA03010875A MX PA03010875 A MXPA03010875 A MX PA03010875A
Authority
MX
Mexico
Prior art keywords
compounds
medicament
production
side chain
acid amides
Prior art date
Application number
MXPA03010875A
Other languages
English (en)
Inventor
Kleemann Heinz-Werner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA03010875A publication Critical patent/MXPA03010875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invencion se refiere a los compuestos de la formula (I); (ver formula) en la cual, R(1)-R(7) tienen los significados que se dan en las reivindicaciones. Estos compuestos actuan en el canal de potasio Kv1.5 e inhiben un flujo de potasio en el atrio o auricula del corazon humano; se les denomina activadores del retardo, de accion ultra rapida. Por lo cual, son particularmente convenientes para utilizarlos como sustancias antiarritmicas, activas, novedosas, en especial en el tratamiento y profilaxis de arritmia auricular, p.ej., en la fibrilacion auricular (FA) o fluter auricular.
MXPA03010875A 2001-06-12 2002-05-31 AMIDAS DE ACIDOS ANTRANILICOS CON CADENA LATERAL DE HETEROARILSULFONILO, PROCEDIMIENTO PARA SU PREPARACIoN SU EMPLEO COMO MEDICAMENTO O AGENTE DE DIAGNOSTICO ASI COMO PREPARADOS FARMACeUTICOS QUE LAS CONTIENEN. MXPA03010875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2002/005956 WO2002100825A2 (de) 2001-06-12 2002-05-31 Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe

Publications (1)

Publication Number Publication Date
MXPA03010875A true MXPA03010875A (es) 2004-02-17

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010875A MXPA03010875A (es) 2001-06-12 2002-05-31 AMIDAS DE ACIDOS ANTRANILICOS CON CADENA LATERAL DE HETEROARILSULFONILO, PROCEDIMIENTO PARA SU PREPARACIoN SU EMPLEO COMO MEDICAMENTO O AGENTE DE DIAGNOSTICO ASI COMO PREPARADOS FARMACeUTICOS QUE LAS CONTIENEN.

Country Status (41)

Country Link
US (2) US6903216B2 (es)
EP (1) EP1399423B9 (es)
JP (1) JP4422477B2 (es)
KR (1) KR100863924B1 (es)
CN (1) CN1247544C (es)
AR (1) AR036045A1 (es)
AT (1) ATE378318T1 (es)
AU (1) AU2002316939B2 (es)
BG (1) BG108415A (es)
BR (1) BR0210374A (es)
CA (1) CA2450076C (es)
CO (1) CO5540283A2 (es)
CR (1) CR7140A (es)
CY (1) CY1107427T1 (es)
CZ (1) CZ20033361A3 (es)
DE (2) DE10128331A1 (es)
DK (1) DK1399423T3 (es)
EC (1) ECSP034883A (es)
EE (1) EE05196B1 (es)
ES (1) ES2295360T3 (es)
HK (1) HK1065316A1 (es)
HR (1) HRP20031028A2 (es)
HU (1) HUP0400159A3 (es)
IL (2) IL159247A0 (es)
MA (1) MA27037A1 (es)
MX (1) MXPA03010875A (es)
MY (1) MY138341A (es)
NO (1) NO20035450D0 (es)
NZ (1) NZ530081A (es)
OA (1) OA12631A (es)
PE (1) PE20021066A1 (es)
PL (1) PL364371A1 (es)
PT (1) PT1399423E (es)
RS (1) RS97703A (es)
RU (1) RU2293727C2 (es)
SK (1) SK15222003A3 (es)
TN (1) TNSN03134A1 (es)
TW (1) TWI304400B (es)
UA (1) UA75412C2 (es)
WO (1) WO2002100825A2 (es)
ZA (1) ZA200308520B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
EP1500650A4 (en) * 2002-04-26 2006-08-23 Ishihara Sangyo Kaisha PYRIDINE COMPOUNDS OR SALTS THEREOF AND HERBICIDES CONTAINING SAME
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
PT1651621E (pt) 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
BRPI0516027A (pt) * 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv compostos de sulfonamida
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
NZ572231A (en) * 2006-04-27 2010-12-24 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2011000541A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co Kgaa Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
ES2632954T3 (es) 2009-06-29 2017-09-18 Agios Pharmaceuticals, Inc. Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (es) 2011-07-01 2018-04-28
WO2013112932A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
CN111183129A (zh) * 2017-08-07 2020-05-19 国立大学法人广岛大学 新型邻氨基苯甲酸系化合物、使用了该化合物的Pin1抑制剂、炎症性疾病及癌症的治疗剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155662A1 (en) 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
CA2336807C (en) 1998-07-08 2010-04-13 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
AU754204B2 (en) 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
IL146513A0 (en) * 1999-06-24 2002-07-25 Smithkline Beecham Corp Macrophage scavenger receptor antagonists
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
US20030114499A1 (en) 2003-06-19
PL364371A1 (en) 2004-12-13
CY1107427T1 (el) 2012-12-19
OA12631A (fr) 2006-06-14
KR100863924B1 (ko) 2008-10-17
HUP0400159A3 (en) 2008-10-28
NO20035450D0 (no) 2003-12-08
HUP0400159A2 (hu) 2004-07-28
UA75412C2 (en) 2006-04-17
DK1399423T3 (da) 2008-03-17
ECSP034883A (es) 2004-01-28
HRP20031028A2 (en) 2005-10-31
ES2295360T3 (es) 2008-04-16
CO5540283A2 (es) 2005-07-29
PE20021066A1 (es) 2003-01-21
IL159247A0 (en) 2004-06-01
RU2293727C2 (ru) 2007-02-20
EP1399423A2 (de) 2004-03-24
CR7140A (es) 2004-04-15
PT1399423E (pt) 2008-02-07
CN1247544C (zh) 2006-03-29
TWI304400B (en) 2008-12-21
NZ530081A (en) 2005-07-29
JP4422477B2 (ja) 2010-02-24
BR0210374A (pt) 2004-07-13
RS97703A (en) 2006-12-15
CZ20033361A3 (cs) 2004-05-12
CA2450076C (en) 2010-11-30
SK15222003A3 (sk) 2004-06-08
TNSN03134A1 (en) 2005-12-23
BG108415A (en) 2004-07-30
MA27037A1 (fr) 2004-12-20
ZA200308520B (en) 2004-09-06
KR20040030668A (ko) 2004-04-09
RU2004100302A (ru) 2005-04-10
AR036045A1 (es) 2004-08-04
CN1529695A (zh) 2004-09-15
EE200300558A (et) 2004-02-16
HK1065316A1 (en) 2005-02-18
WO2002100825A3 (de) 2003-12-11
IL159247A (en) 2010-06-16
EP1399423B1 (de) 2007-11-14
JP2004533464A (ja) 2004-11-04
CA2450076A1 (en) 2002-12-19
US6903216B2 (en) 2005-06-07
DE50211213D1 (de) 2007-12-27
EP1399423B9 (de) 2008-02-27
US7235664B2 (en) 2007-06-26
ATE378318T1 (de) 2007-11-15
MY138341A (en) 2009-05-29
US20050137200A1 (en) 2005-06-23
AU2002316939B2 (en) 2006-11-23
WO2002100825A2 (de) 2002-12-19
DE10128331A1 (de) 2002-12-19
EE05196B1 (et) 2009-08-17

Similar Documents

Publication Publication Date Title
TNSN03134A1 (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds
TNSN03084A1 (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
HK1066539A1 (en) Ortho-substituted nitrogen-containing bisaryl compounds use as potassium channel inhibitors
YU42503A (sh) Arilovani furan-1 tiofen-amidi-karbonske kiseline sa blokirajućim dejstvom kalijumovog kanala
CY1106178T1 (el) 2’- υποκατεστημενα 1,1’-διφαινυλο-2-καρβοξαμιδια, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακου καθως και φαρμακευτικα παρασκευασματα που τα πepιεχουν
AR031430A1 (es) Compuestos de bisarilo orto, meta-sustituidos, procedimientos para su preparacion, su utilizacion como medicamento como tambien los preparados farmaceuticos que los contienen
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
GR3036184T3 (en) Heterocyclic diaryl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof
WO1999043636A3 (en) Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
BR0206791A (pt) Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto
WO2022238565A3 (en) Modulators of sortilin activity
HRP20050815A2 (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
WO2024006974A3 (en) Antimalarial compounds
WO2023154804A3 (en) Method of treating spinal cord injury and composition for use therein
WO2021125910A3 (ko) NDPK 활성제 및 H-prune 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물
BG106025U (en) Medicamentous form

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status